NF 340: Unmasking the P2Y11 Pathway in Cancer Invasion Research

Introduction: P2Y11 Antagonists and the New Era of Purinergic Signaling Research

The modulation of purinergic signaling through selective antagonists like NF 340 is reshaping the landscape of cell signaling and cancer research. The P2Y11 receptor, a unique member of the GPCR (G protein-coupled receptor) superfamily, orchestrates a complex network of downstream pathways governing immune response, inflammation, and tumor progression. NF 340 (sodium (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate) stands out as a potent, selective, and research-grade P2Y11 antagonist, offering scientists a robust tool to interrogate this axis with unprecedented precision.

NF 340: Structure, Properties, and Handling

NF 340 (SKU: B7508) is supplied by APExBIO as a beige solid with a molecular weight of 986.84 and the chemical formula C₃₇H₂₆N₄Na₄O₁₅S₄. Its solubility in water is less than 19.74 mg/ml, and it is recommended to store the compound at -20°C for optimal stability. Due to its chemical profile, solutions should be freshly prepared and used promptly. NF 340 is strictly for research applications and not intended for diagnostic or therapeutic uses, as detailed in the product information.

Mechanism of Action: Targeting the P2Y11 Receptor

Purinergic receptors are pivotal in cellular communication, with the P2Y11 subtype mediating both G_s and G_q protein signaling. NF 340 acts as a highly selective antagonist of the P2Y11 receptor, effectively inhibiting its activity and thereby modulating downstream GPCR signaling pathways. This selective inhibition allows for the dissection of P2Y receptor signaling from other closely related purinergic pathways, providing clarity in complex experimental systems.

The specificity of NF 340 offers a distinct advantage for studying pathways such as cAMP production, calcium mobilization, and the regulation of immune and inflammatory responses. In particular, the ability to block P2Y11 without off-target interference is critical in models exploring the interplay between GPCR signaling and disease phenotypes.

Reference Insight Extraction: QPRT, Myosin Phosphorylation, and the P2Y11 Axis in Breast Cancer

A landmark study by Liu et al. (Frontiers in Endocrinology, 2021) revealed that quinolinate phosphoribosyltransferase (QPRT), a key enzyme in NAD⁺ biosynthesis, promotes breast cancer cell invasiveness by enhancing myosin light chain phosphorylation. Critically, the study demonstrated that this pro-invasive effect is mediated through purinergic signaling, specifically via the P2Y11 receptor. The use of NF 340 as a P2Y11 antagonist reversed QPRT-induced invasiveness and phosphorylation events, establishing a functional link between metabolic reprogramming, purinergic signaling, and cytoskeletal dynamics. This finding is especially meaningful for practical assay design: by leveraging NF 340, researchers can directly interrogate the contribution of P2Y11-mediated signaling in cancer cell migration, invasion, and potentially in the regulation of the tumor microenvironment. The ability to uncouple QPRT-driven effects from other pathways using NF 340 offers a uniquely precise experimental approach not available with broader-acting inhibitors.

Protocol Parameters

• Compound Preparation: Dissolve NF 340 in sterile water or DMSO to a final concentration of ≤19.74 mg/ml, ensuring immediate use to maintain activity and avoid degradation.
• Cellular Assays: For breast cancer invasion assays, pre-treat cells with 1–10 μM NF 340 for 30–60 minutes prior to stimulation with QPRT or invasion inducers, as described in the reference study.
• Storage: Store NF 340 powder at -20°C. Avoid repeated freeze-thaw cycles. Prepare fresh working solutions for each experiment for optimal reproducibility.
• Co-Inhibitor Experiments: To dissect pathway specificity, combine NF 340 with ROCK, MLCK, or PLC inhibitors following sequential or parallel application strategies based on the experimental hypothesis.
• Negative Controls: Include vehicle controls and, where possible, non-P2Y11 antagonists to confirm selectivity.

Comparative Analysis: NF 340 Versus Alternative Approaches

Existing content, such as the guide on precision GPCR signaling inhibition, emphasizes troubleshooting and the operational value of P2Y11 antagonists in immunology models. However, this article advances the conversation by focusing on the unique intersection of metabolic enzymes, such as QPRT, and purinergic receptor signaling in cancer invasion. Unlike generalized protocols for GPCR inhibition, the integration of NF 340 into metabolic signaling assays opens new avenues for dissecting how NAD⁺ pathway dysregulation drives malignancy through defined receptor targets.

Meanwhile, the scenario-based analysis found in Bendamustine Kits provides critical insights into practical troubleshooting but does not address the mechanistic bridge between metabolic regulation and cell motility. Here, we highlight not only the technical application but also the biological rationale, demonstrating how NF 340 enables a systems-biology approach to cancer research.

Advanced Applications: Modulating Inflammation and Immunology Pathways

The role of P2Y11 in immune regulation extends beyond cancer, encompassing inflammation pathway modulation and the orchestration of innate and adaptive immune responses. NF 340's selectivity allows researchers to pinpoint the contribution of P2Y11-mediated signaling in models of sepsis, autoimmunity, and chronic inflammatory disease.

While previous articles such as PR-171 have explored the compound's utility in dissecting GPCR signaling in immunology, our focus on the metabolic–purinergic interface offers a novel experimental context. By integrating NF 340 into co-culture assays or complex tissue models, scientists can evaluate how immune cell function and cytokine release are modulated by P2Y11 activity, providing a platform for translational discoveries in both cancer and immunology.

Why This Cross-Domain Matters, Maturity, and Limitations

The QPRT–P2Y11–myosin axis exemplifies a mature cross-domain bridge between cancer metabolism and cell signaling. Applying NF 340 in this context allows researchers to test targeted hypotheses regarding both metabolic and receptor-driven mechanisms of tumor invasion. However, it is crucial to acknowledge that while in vitro and preclinical models yield mechanistic clarity, extrapolation to clinical outcomes will require further validation. The current evidence base, as outlined in the reference study, provides a robust scientific rationale but does not yet encompass therapeutic translation.

Conclusion and Future Outlook

NF 340, as offered by APExBIO, is more than a traditional GPCR signaling tool; it is a precision instrument for unraveling the interplay between metabolic reprogramming and receptor-mediated events in cancer and immunology. Leveraging this compound in sophisticated experimental systems—especially those investigating QPRT-driven pathways—promises deeper mechanistic insight and the potential for identifying novel intervention points. As the translational relevance of the P2Y11 axis continues to emerge, NF 340 will remain an indispensable asset for cutting-edge research.

Looking ahead, the implications of the QPRT–P2Y11 link for tumor progression and immune modulation warrant further exploration, particularly in the context of patient-derived models and in vivo studies. The evidence to date, centered on the foundational findings of Liu et al., underscores the importance of targeted cell signaling inhibitors in clarifying disease mechanisms and guiding the next generation of translational assays.